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Cancer is a disease of the genome and the epigenome. Previous studies have 
shown that genomic changes such as mutations, copy number variation, and 
genomic rearrangements drive cancer evolution. In this issue of Cancer Cell, 
Landau et al. add epigenomic changes, specifically locally disordered DNA 
methylation, to cancer’s evolutionary trajectory. 
 
Deep genomic sequencing technologies are beginning to resolve the underlying 
complexities of solid and hematologic cancers. Peter Nowell’s proposed model for 
cancer evolution suggesting that cancers evolve through branched evolutionary 
trajectories fuelled by genomic instability is now increasingly being accepted as a 
basis for therapeutic failure and the increasing mismatch between cost and clinical 
benefit from current targeted therapeutic approaches (Nowell, 1976) As Nowell 
predicted in 1976, “One may ultimately have to consider each advanced malignancy 
as an individual therapeutic problem.” 
 
Work over the last 3 decades has revealed how diversity within tumors can be driven 
at many levels. Genomic instabilities can be initiated by deficiencies in DNA repair, 
DNA replication stress, telomere dysfunction, genome doubling events, and mitotic 
aberrations resulting in abnormal chromosome-spindle attachments precipitating 
whole chromosomal instabilities (reviewed in Burrell et al., 2013). Such genome 
instability processes may also be dynamic over space and time. As the resolution of 
cancer genomic analysis improves, so does an appreciation that the majority of solid 
tumors harbor at least one mechanism of genome instability that promotes further 
evolution and adaptation.  
 
It has been appreciated for many years that diversity within individual tumors, 
manifested by chromosomal instability, is associated with poor outcome. Deep 
sequencing analyses have added to these observations. For example, through deep 
sequencing analysis of chronic lymphocytic leukemia (CLL). the presence of 
subclonal driver events was associated with poorer outcome (Landau et al., 2013) . 
Emerging data suggest that diversity at any level is sufficient to influence clinical 
outcomes. Indeed, Carlo Maley and colleagues investigated this proposition in 
Barrett’s esophagus, the pre-invasive stage preceding the onset of esophageal 
carcinoma, examining multiple genetic and epigenetic drivers of diversity. The 
authors concluded that all diversity measures, both genetic and epigenetic, were 
strongly associated with clinical risk of progression  (Merlo et al., 2010). 
 
It is also appreciated that genetically similar cells may behave differently in the face 
of identical selection pressures. Altered epigenetic states are thought to be a 
mechanism through which these observations can be explained. For example, 
minority drug tolerant persistor cells result in drug resistance dependent on the 
histone demethylase JARID1A, that which can be both dynamic and transient 
(Sharma et al., 2010). These data suggest the need for a comprehensive 
understanding of both the cancer genome and epigenome to predict tumor cell 
behaviour. It is the understanding of the latter into which the study in this issue of 
Cancer Cell by Landau and colleagues sheds new light (Landau et al., 2014). 
 
A defining feature of epigenetics is the ability to stably switch between different 
biological states. Typically, this can result in the expression of affected genes to be 
switched on or off or genome stability to be maintained or impaired. This process of 
switching allows for many different genetic programs to be run from the same 
genome, giving rise to many different epigenomes. The temporal and spatial 
regulation of these epigenomes are exquisitely controlled during normal development 
but severely disrupted in cancer. A common mechanism for epigenomic disruption is 
stochasticity whereby changes are introduced randomly that lead to gain or loss of 
DNA methylation at certain CpG dinucleotides, the preferred sites of DNA 
methylation in mammalian cells including cancer cells. In addition, such seemingly 
stochastic changes may also be mediated by genetic variants as proposed in the 
inherited stochastic variation model, which provides a mechanism to explain an 
epigenetic role in selectable phenotypic variation (Irizarry and Feinberg, 2010).  
 
Figure 1A illustrates three common scenarios of DNA methylation (DNAm) changes 
that have been observed in multiple cancers by comparison with normal tissue. As 
the name implies, variably methylated regions (VMRs) display oscillating gain and 
loss of DNAm. Their ‘noisy’ appearance inspired a model whereby the epigenome 
can modulate cellular plasticity by regulating the effects of noise and thus explain the 
observed increase in VMRs and gene expression contributing to cancer 
heterogeneity (Pujadas and Feinberg, 2012). Regions of long-range epigenetic 
silencing (LRES) and activation (LREA) are defined by gain and loss of DNAm 
respectively and have been shown to remodel large domains of the cancer 
epigenome (reviewed in Stirzaker et al., 2014). 
 
What differentiates the study by Landau and colleagues (Landau et al., 2014), which 
focuses on CLL, from previous studies investigating intra-tumor DNAm heterogeneity, 
is that they used deep bisulfite sequencing. This allowed them to assess DNAm 
heterogeneity at single molecules or reads derived from individual cancer cells rather 
than aggregated values from populations of cancer cells. As illustrated in Figure 1B, 
some reads were found to be methylation concordant (CR) while others were found 
to be discordant (DR), consistent with increased stochastic heterogeneity in the 
corresponding leukemic cells. To quantify this heterogeneity, the authors devised a 
new measure - ‘Proportion of Discordant Reads’ (PDR) – which provides an index for 
intra-tumor DNAm heterogeneity which is akin to the intra-tumor heterogeneity ratio 
index (ITH) already in use for quantifying intra-tumor genetic heterogeneity from the 
TRACERx study (Jamal-Hanjani et al., 2014). By measuring the PDR index across 
promoters in a cohort of patients with CLL, Landau et al. established that increasing 
PDR levels are associated with adverse clinical outcome (Figure 1C).  
 
Looking ahead, the hope is that this new approach will improve our ability to 
determine, and one day attenuate, the background DNAm in cancer. This would 
thereby allow for more accurate identification of positively selected methylation 
changes, the elusive epigenetic drivers of cancer progression and evolution.  If 
successful, we will be one step closer to solving Nowell’s individualized therapeutic 
problem, by limiting the epigenetic fuel for cancer progression. 
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Figure 1: Illustration of intra-tumor DNA methylation heterogeneity. [A] Major 
types of DNA methylation (DNAm) heterogeneity include variably methylated regions 
(VMR), long-range epigenetic silencing (LRES), and long-range epigenetic activation 
(LREA). [B] Schematic bisulfite sequencing reads showing concordant (CR) and 
discordant (DR) DNAm and formula for calculation the proportion of discordant reads 
(PDR). [C] PDR differs in patients with chronic lymphocytic leukemia (CLL) and is 
associated with adverse clinical outcome. 
 
 
